Clinical trials
Prostatitis clinical trials
Below are recruiting prostatitis clinical trials, each written for real people, not researchers. We’re tracking 1,360 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07568613Recruiting
PSMA PET/CT versus MRI for mapping prostate cancer
This trial compares two imaging techniques—PSMA PET/CT and MRI—to see which one better finds and outlines prostate cancer tumors. You'll receive both scans to help doctors understand which method works best for newly diagnosed prostate cancer.
LimassolAges 18 years+ - NCT07562386Recruiting
Prostate Surgery Outcomes and Patient Satisfaction Study
This study compares two surgical techniques for enlarged prostate (benign prostatic hyperplasia, or BPH) to see which one works better and how satisfied patients are afterward. If you have moderate prostate enlargement and urinary symptoms, this trial might help improve your treatment.
HamarAges Up to 80 years - NCT07545811RecruitingPhase 1
JANX014 for Advanced Prostate Cancer
This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.
La Jolla, CaliforniaAges 18 years+ - NCT07526675Recruiting
Same-day prostate biopsy and heat treatment for cancer
This trial combines a biopsy (tissue sampling) with a heat-based ablation procedure in one visit to diagnose and treat early prostate cancer while also relieving severe urinary symptoms. It may help patients who need quick treatment and early discharge.
Banhā, Qalyubia GovernorateAges 1.5 years+ - NCT07531329Recruiting
Delayed PSMA imaging to detect aggressive prostate cancer
This study tests whether a special type of imaging scan (PSMA PET/CT with delayed imaging) can better identify aggressive prostate cancer in men who haven't had a biopsy yet. The goal is to help doctors decide who really needs a biopsy and avoid unnecessary procedures.
Lanzhou, GansuAges 18 years+ - NCT06657131Recruiting
PSMA PET scan for prostate cancer recurrence
This trial looks at how well a special PET scan (called PSMA PET) can find prostate cancer that has come back after treatment. It uses a radioactive tracer to spot cancer cells. Your doctor may already have ordered this scan as part of your regular care.
Düsseldorf, North Rhine-WestphaliaAges 18 years+ - NCT07468903Recruiting
Focal radiation for prostate cancer with HDR brachytherapy
This trial tests a targeted radiation treatment called HDR brachytherapy for prostate cancer that hasn't spread. It aims to treat only the cancer spots seen on MRI, which may reduce side effects.
Los Angeles, CaliforniaAges 40 years+ - NCT07426055RecruitingPhase 2/Phase 3
Prostate cancer radiation boost comparison study
This trial compares two types of radiation treatments for prostate cancer that has not spread to lymph nodes or other parts of the body. It tests whether adding a higher dose of radiation to the main tumor helps control the cancer better than standard radiation alone.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07422597Recruiting
MRI or risk calculator for suspected prostate cancer
This trial compares using an upfront MRI versus a risk calculator to decide who needs a prostate biopsy. It may help men with suspected localized prostate cancer avoid unnecessary biopsies.
LevangerAges 50–75 - NCT07416227Recruiting
Comparing two treatments for enlarged prostate
This trial compares two minimally invasive procedures for an enlarged prostate (benign prostatic hyperplasia). It tests whether water vapor thermal therapy or prostatic artery embolization works better to improve urinary symptoms.
Cairo, AbbassiaAges 50 years+ - NCT07414940RecruitingPhase 1/Phase 2
Actinium-225 PSMA for advanced prostate cancer after Lu-177
This trial tests a new targeted radiation drug called actinium-225 PSMA for men with advanced prostate cancer that has stopped responding to hormone therapy and has already been treated with Lu-177 PSMA (a similar targeted radiation therapy). It aims to see if this stronger radiation can help when the first type stops working.
LondonAges 18 years+ - NCT07407608Recruiting
Radiation therapy for unfavorable prostate cancer
This trial tests a type of focused radiation therapy for men with intermediate or high-risk prostate cancer that hasn't spread. It aims to improve outcomes by targeting the main tumor seen on MRI.
Monza, MBAges 18–90 - NCT07393867RecruitingPhase 2
PSMA-guided radiation boost for prostate cancer
This trial tests a special type of radiation therapy (SBRT) that delivers a higher dose directly to the main tumor in your prostate, guided by a PSMA PET scan. It aims to improve cancer control while limiting side effects.
Boston, MassachusettsAges 18 years+ - NCT06242119Recruiting
Testing a new PET scanner prototype
This study is testing a new type of PET scanner (called J-PET) to see if it works as well as current PET/CT machines. If you are already scheduled for a whole-body PET/CT scan, participating would mean your scan is done with this experimental scanner instead.
KrakowAges 18 years+ - NCT07339267RecruitingPhase 1
Safety and dosing study of ASP5541 in Chinese men with metastatic prostate cancer
This study tests a new drug called ASP5541 for Chinese men with prostate cancer that has spread. The drug is given as a shot, and researchers want to see if it is safe and what the right dose might be.
Beijing, Beijing MunicipalityAges 18–85 - NCT06866782Recruiting
European study on advanced imaging for prostate cancer
This study is a European registry that collects information from men with prostate cancer who need advanced imaging (like PSMA PET/CT or MRI) to check if the cancer has spread. By joining, you help researchers learn more about how these scans improve care.
LeuvenAges 18 years+ - NCT07285057RecruitingPhase 2
New PET scan for men with low-risk prostate cancer on active surveillance
This trial tests a new imaging test called rhPSMA-7.3 (18F) PET/CT to see if it can better detect prostate cancer in men who are on active surveillance because their cancer is considered low-risk or favorable intermediate-risk. You would also get an MRI and a biopsy as part of the study.
New York, New YorkAges 18 years+ - NCT07200830RecruitingPhase 3
Testing different schedules of a targeted radiation drug for advanced prostate cancer
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
Anchorage, AlaskaAges 18 years+ - NCT07162194Recruiting
Testing AI for reading prostate MRI scans
This study uses an artificial intelligence (AI) program to read MRI scans of the prostate and compare its findings with those of expert radiologists. The goal is to see if the AI can detect prostate cancer as accurately as the human experts, which might help in future diagnosis and treatment planning.
Los Angeles, CaliforniaAges 20 years+ - NCT05470127Recruiting
Testing a new prostate biopsy needle against the usual one
This study compares a new prostate biopsy system/needle with the standard biopsy needle during your scheduled prostate biopsy. It looks at how well the procedure collects tissue for diagnosis and how the tissue samples compare.
Cartersville, GeorgiaAges 18–90 - NCT07090148RecruitingPhase 1
Vaccine plus immunotherapy for prostate cancer that has returned
This trial tests a combination of a DNA vaccine (pTVG-HP) and an immunotherapy drug (nivolumab) along with targeted radiation or ablation of remaining cancer spots. It is for men whose prostate cancer has come back after surgery but hasn't spread widely.
Madison, WisconsinAges 18 years+ - NCT07052214RecruitingPhase 3
PSMA PET plus MRI to find prostate cancer
This trial tests if combining a PSMA PET scan with an MRI can better detect clinically significant prostate cancer than MRI alone. It may help men who have not had a prostate biopsy before and have certain risk factors.
Los Angeles, CaliforniaAges 18 years+ - NCT07028853RecruitingPhase 3
New drug combo for advanced prostate cancer
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
Huntsville, AlabamaAges 18 years+ - NCT07005154RecruitingPhase 2
Study of ASP5541 for metastatic prostate cancer
This study tests an experimental drug called ASP5541 for men with metastatic prostate cancer (either hormone-sensitive or castration-resistant). It aims to see if the drug can slow cancer growth and improve outcomes when added to standard hormone therapy.
Huntsville, AlabamaAges 18 years+
Hear when a new Prostatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostatitis?
- Yes. Clin2 currently lists 1,360 recruiting prostatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.